Estropipate
Active ingredient: Estropipate
In short: Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause.
What is Estropipate used for?
Estropipate tablets are indicated in the:
Treatment of moderate to severe vasomotor symptoms associated
with the menopause.
Treatment of moderate to severe symptoms of vulval and vaginal
atrophy associated with the menopause. When prescribing solely for the treatment
of symptoms of vulvar and vaginal atrophy, topical vaginal products should be
considered.
Treatment of hypoestrogenism due to hypogonadism, castration or
primary ovarian failure.
Prevention of postmenopausal osteoporosis. When prescribing
solely for the prevention of postmenopausal osteoporosis, therapy should only be
considered for women at significant risk of osteoporosis and for whom
non-estrogen medications are not considered to be appropriate.
The mainstays for decreasing the risk of postmenopausal osteoporosis are
weight-bearing exercise, adequate calcium and vitamin D intake, and when
indicated, pharmacologic therapy. Postmenopausal women require an average of
1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium
supplementation may be helpful for women with suboptimal dietary intake. Vitamin
D supplementation of 400-800 IU/day may also be required to ensure adequate
daily intake in postmenopausal women.
âš Boxed warning (FDA's strongest warning)
Close clinical surveillance of all women taking estrogens is
important. Adequate diagnostic measures, including endometrial sampling when
indicated, should be undertaken to rule out malignancy in all cases of
undiagnosed persistent or recurring abnormal vaginal bleeding. There is no
evidence that the use of “natural” estrogens result in a different endometrial
risk profile than “synthetic” estrogens at equivalent estrogen doses.
Estrogens with and without progestins should not be used for the
prevention of cardiovascular disease.
The Women’s Health Initiative (WHI) study reported increased risks of
myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and
deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5
years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with
medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo.
The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI,
reported increased risk of developing probable dementia in postmenopausal women
65 years of age or older during 4 years of treatment with oral conjugated
estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown
whether this finding applies to younger postmenopausal women or to women taking
estrogen alone therapy.
Other doses of conjugated estrogens with medroxyprogesterone
acetate, and other combinations and dosage forms of estrogens and progestins
were not studied in the WHI clinical trials and, in the absence of comparable
data, these risks should be assumed to be similar. …
Estropipate dosage
When estrogen is prescribed for a woman with a uterus, progestin
should also be initiated to reduce the risk of endometrial cancer. A woman
without a uterus does not need progestin. Use of estrogen, alone or in
combination with a progestin, should be with the lowest effective dose and for
the shortest duration consistent with treatment goals and risks for the
individual woman. Patients should be reevaluated periodically as clinically
appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is
still necessary For women who have a uterus, adequate diagnostic measures,
such as endometrial sampling, when indicated, should be undertaken to rule out
malignancy in cases of undiagnosed persistent or recurring abnormal vaginal
bleeding.
For treatment of moderate to severe vasomotor symptoms, vulval
and vaginal atrophy associated with the menopause, the lowest dose and regimen
that will control symptoms should be chosen and medication should be
discontinued as promptly as possible. Attempts to discontinue or taper
medication should be made at 3month to 6-month intervals. Usual dosage
ranges:
Vasomotor symptoms—One estropipate 0.75
mg tablet to two estropipate 3 mg tablets per day. The lowest dose that will
control symptoms should be chosen. If the patient has not menstruated within the
last two months or more, cyclic administration is started arbitrarily. If the
patient is menstruating, cyclic administration is started on day 5 of
bleeding.
Vulval and vaginal atrophy—One
estropipate 0.75 mg tablet to two estropipate 3 mg tablets daily, depending upon
the tissue response of the individual patient. The lowest dose that will control
symptoms should be chosen. Administer cyclically.
For treatment of female hypoestrogenism due to hypogonadism,
castration, or primary ovarian failure. Usual dosage ranges:
Female hypogonadism—A daily dose of one estropipate 1.5 mg
tablet to three estropipate 3 mg tablets may be given for the first three weeks
of a theoretical cycle, followed by a rest period of eight to ten days. The
lowest dose that will control symptoms should be chosen. If bleeding does not
occur by the end of this period, the same dosage schedule is repeated. The
number of courses of estrogen therapy necessary to produce bleeding may vary
depending on the responsiveness of the endometrium. If satisfactory withdrawal
bleeding does not occur, an oral progestogen may be given in addition to
estrogen during the third week of the cycle.
Female
castration or primary ovarian failure—A daily dose of one estropipate 1.5
mg tablet to three estropipate 3 mg tablets may be given for the first three
weeks of a theoretical cycle, followed by a rest period of eight to ten days. …
How to take Estropipate — instructions & advice from the label
Estropipate Tablets USP
Read this PATIENT INFORMATION before you start taking estropipate tablets and
read what you get each time you refill estropipate tablets. There may be new
information. This information does not take the place of talking to your health
care provider about your medical condition or your treatment.
WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT
ESTROPIPATE (AN ESTROGEN HORMONE)?
• Estrogens increase the chances of getting cancer of the uterus.Report any unusual vaginal bleeding right away while you are taking estrogens.
Vaginal bleeding after menopause may be a warning sign of cancer of the uterine
(womb). Your health care provider should check any unusual vaginal bleeding to
find out the cause.
• Do not use estrogens with or without progestins to prevent heart disease,
heart attacks or strokes.Using estrogens with or without progestins may increase your chances of getting
heart attacks, strokes, breast cancer and blood clots. You and your health care
provider should talk regularly about whether you still need treatment with
estropipate tablets.
What is estropipate?
Estropipate is a medicine that contains estrogen hormones. …
Warnings & precautions
Do not take this medicine if: Estropipate tablets should not be used in women with any of the
following conditions:
Undiagnosed abnormal genital bleeding.
Known, suspected, or history of cancer of the breast.
Known or suspected estrogen-dependent neoplasia.
Active deep vein thrombosis, pulmonary embolism or history of
these conditions.
Active or recent (e.g., within the past year) arterial
thromboembolic disease (e.g., stroke, myocardial infarction).
Liver dysfunction or disease.
Estropipate tablets should not be used in patients with known
hypersensitivity to its ingredients.
Known or suspected pregnancy. There is no indication for
estropipate tablets in pregnancy.
There appears to be little or no increased risk of birth defects in children
born to women who have used estrogens and progestins from oral contraceptives
inadvertently during early pregnancy.
Enter section text here
Studies of the addition of a progestin for 10 or more days of a
cycle of estrogen administration, or daily with estrogen in a continuous
regimen, have reported a lowered incidence of endometrial hyperplasia than would
be induced by estrogen treatment alone. Endometrial hyperplasia may be a
precursor to endometrial cancer.
There are, however, possible risks that may be associated with the use of
progestins with estrogens compared to estrogen-alone regimens. These include a
possible increased risk of breast cancer, adverse effects on lipoprotein
metabolism (e.g., lowering HDL, raising LDL) and impairment of glucose
tolerance.
In a small number of case reports, substantial increases in blood
pressure have been attributed to idiosyncratic reactions to estrogens. In a
large, randomized, placebo-controlled clinical trial, a generalized effect of
estrogens on blood pressure was not seen. Blood pressure should be monitored at
regular intervals with estrogen use. …
Estropipate side effects
See
BOXED
WARNINGS
,
WARNINGS
and
PRECAUTIONS
.
The following additional adverse reactions have been reported with estrogens
and/or progestin therapy.
Changes in vaginal bleeding pattern and abnormal withdrawal bleeding or flow;
breakthrough bleeding; spotting; dysmenorrhea; increase in size of uterine
leiomyomata; vaginitis; including vaginal candidiasis; change in amount of
cervical secretion; changes in cervical ectropion; ovarian cancer; endometrial
hyperplasia; endometrial cancer.
Tenderness, enlargement, pain, nipple discharge, galactorrhea; fibrocystic
breast changes; breast cancer.
Deep and superficial venous thrombosis; pulmonary embolism; thrombophlebitis;
myocardial infarction; stroke; increase in blood pressure.
Nausea, vomiting; abdominal cramps, bloating; cholestatic jaundice; increased
incidence of gallbladder disease; pancreatitis; enlargement of hepatic
hemangiomas.
Chloasma or melasma that may persist when drug is discontinued; erythema
multiforme; erythema nodosum; hemorrhagic eruption; loss of scalp hair;
hirsutism; pruritus, rash.
Retinal vascular thrombosis; steepening of corneal curvature; intolerance to
contact lenses.
Headache, migraine, dizziness; mental depression; chorea; nervousness; mood
disturbances; irritability; exacerbation of epilepsy; dementia. …
About this medicine
Estropipate (formerly piperazine estrone sulfate), is a natural estrogenic
substance prepared from purified crystalline estrone, solubilized as the sulfate
and stabilized with piperazine. It is appreciably soluble in water and has
almost no odor or taste — properties which are ideally suited for oral
administration. The amount of piperazine in estropipate is not sufficient to
exert a pharmacological action. Its addition ensures solubility, stability, and
uniform potency of the estrone sulfate. Chemically estropipate, molecular
weight: 436.56, is represented by estra-1,3,5(10)-trien-17-one,3-(sulfooxy)-,
compound with piperazine (1:1). The structural formula may be represented as
follows:
C18H22O5S.C4H10N2 | M.W.=436.56
Estropipate is available as tablets for oral administration containing either
0.75 mg, 1.5 mg, 3 mg, or 6 mg estropipate (calculated as sodium estrone sulfate
0.625 mg, 1.25 mg, 2.5 mg and 5 mg, respectively). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 03cdbf5b-b572-448f-80e9-b3e812959901. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone